


MICRO-X

REIMAGINING MEDICAL IMAGING CT

Enabled by proprietary carbon nanotube X-ray technology

Kingsley Hall
Chief Executive Officer
25 June 2026



IMPORTANT NOTICE



THIS PRESENTATION HAS BEEN APPROVED BY THE BOARD OF MICRO-X LIMITED

SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX:MX1). The Presentation is a summary only which is current only as at the date of this Presentation or as at the relevant dates set out in the Presentation (as applicable) and does not contain all the information about the Company's activities, assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with ASX Limited and the Australian Securities & Investments Commission (ASIC). The information in this Presentation is of a general nature, and does not purport to be complete or comprise all of the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). The Company is under no obligation to update this Presentation. The information in this Presentation remains subject to change by the Company without notice.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information including statements regarding the Company's intentions, beliefs or current expectations about the Company's business and operations, and market conditions. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Estimates of, indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Such expectations, estimates, projections and information are provided as a general guide only and are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation, and the information contained in it, is for information purposes only and does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, this Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States and the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States.

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so. The distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

IMPORTANT NOTICE - CONTINUED



NOT INVESTMENT ADVICE

The information contained in this Presentation is not financial product, investment, legal, taxation or other advice or any recommendation to acquire securities in the Company. No reliance may be placed for any purpose whatsoever on the information contained in this Presentation. This Presentation does not and will not form any part of any contract for the acquisition of securities in the Company. This Presentation has been prepared without taking into account your investment objectives, financial situation or particular needs. The Presentation is in summary form and does not purport to be exhaustive. This Presentation should be read in conjunction with the Company's periodic disclosure announcements which are available to download at www.micro-x.com. Before making an investment decision, you should make your own enquiries and investigations, and consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs, having regard to the merits or risks involved. None of the Company, its respective related bodies corporate, shareholders or affiliates, and any of their respective officers, directors, employees, affiliates, agents, representatives or advisers (each a **Limited Party**) guarantees or makes any representations or warranties, express or implied, as to or takes responsibility for, the accuracy, reliability, completeness, correctness or fairness of the information, opinions, forecasts, reports, estimates and conclusions contained in this Presentation. No Limited Party represents or warrants that this Presentation is complete or that it contains all information that a prospective investor or purchaser or other stakeholder may require in evaluating the information contained in this Presentation. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss (direct or indirect) arising from the use of or reliance on information contained in this Presentation including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this Presentation including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

INVESTMENT RISK

An investment in securities in the Company is subject to investment and other known and unknown risks, some of which are beyond the control of the Company. The Company does not guarantee any particular rate of return or the performance of its securities, nor does it guarantee any particular tax treatment. You should carefully consider the risks outlined in this Presentation before making an investment decision. The Company does not provide an opinion, accept or assume responsibility for any purpose or to any person to whom this Presentation is shown or into whose hands it may come. The Company makes no representation concerning the appropriateness of this Presentation for anyone and if anyone chooses to use or rely on the Presentation, they do so at their own risk. This Presentation should not be regarded by you as a substitute for the exercise of your own judgment and you are expected to rely on your own due diligence. Nothing contained in the Presentation is, or shall be relied upon as, a promise or representation as to the past or future. The Company, its affiliates, directors, employees and/or agents expressly disclaim any and all liability relating or resulting from inaccurate or incomplete information and the use or reliance of all or any part of the Presentation.

THIRD PARTY INFORMATION

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications. No representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.

DISCLAIMER

None of the Company's advisers, officers, employees or agents have authorised, permitted or caused the issue, despatch or provision of this Presentation nor, except to the extent referred to in this Presentation, made or purported to make any statement in this Presentation. To the maximum extent permitted by law, the Company, its officers, employees, agents or advisers expressly disclaims any and all liability, including without limitation, any liability arising out of fault or negligence, for any direct, indirect, consequential or contingent loss or damage arising from the use of information contained in this Presentation.

EFFECT OF ROUNDING

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation. Totals and percentages are based on whole numbers and may not sum due to rounding.

CURRENCY

All amounts referred to in this presentation as \$ or dollars are Australian dollars and all amounts referred to as US\$ refer to the currency of the United States of America.

THIS PRESENTATION IS APPROVED BY THE BOARD

INVESTMENT HIGHLIGHTS

MICRO-X

World leading CT medtech company taking CT imaging to the patient

MEDICAL CT IMAGING COMPANY	<ul style="list-style-type: none">• Micro-X develops CT Imaging Systems to bring gold-standard imaging beyond conventional CT's constraints to where the patient needs it – ERs, critical care, trauma, ORs, ambulances, rural, battle-front and disaster relief• Proprietary NEX carbon-nanotube X-ray is the only platform delivering a step-change in CT size, weight, power, reliability and durability• 3 CT programs at different maturities – Head CT (human trials), Full Body CT (\$25M ARPA-H), Security CT (\$31.7M DHS & TSA) – all on one NEX platform
SIGNIFICANT FAST-GROWING GLOBAL MARKET	<ul style="list-style-type: none">• Existing Global CT market circa \$12B with in excess of 100,000 systems installed¹• Forecast CAGR 5.4% through 2036 driven by ageing population and increase in chronic illness¹• Patients face increasing difficulty in accessing CT imaging• Micro-X is uniquely positioned at the intersection of CT imaging and healthcare decentralisation
HEAD CT NEAR-TERM VALUE DRIVER	<ul style="list-style-type: none">• Only CT small and portable enough to fit a standard road or air ambulance - developed under \$8M development agreement with Aus. Stroke Alliance• Human imaging trials underway at Royal Melbourne Hospital – 105 patient pivotal stroke study vs conventional CT• TGA/FDA submissions targeted 2027; commercial launch to follow; in-ambulance trials via \$4.4M non-dilutive Aus Govt IGP grant• Total Addressable Market: ~\$9.4B (new In Ambulance market of ~\$4B plus ~\$5.4B future new In Hospital market)²
ARPA-H VALIDATES FULL BODY CT	<ul style="list-style-type: none">• ARPA-H awarded up to \$25.0M (competitive award vs conventional CT vendors) to design and test a Full Body CT for remote/rural use• Solving the global issue of access to quality CT imaging• First laboratory test bench completed March '26; capital-efficient staged pathway building on Head CT platform IP
ROVER: TECHNOLOGY VALIDATION	<ul style="list-style-type: none">• Pathfinder product that proves the core NEX technology works reliably in the real, deployed environments where portable imaging is needed, providing diagnostic quality imaging in hospitals, in-home care, remote and military settings• FDA-cleared, CE-marked, TGA-listed; 400+ units sold across 38 countries• Record \$3.3M Malaysian Ministry of Health order delivered Nov '25• 2026 model upgrade improves customer experience and is driving additional commercial opportunities

IMAGING'S NEXT DISRUPTION CYCLE

Medical imaging is not evolving – it is resetting. NEX is the new architecture

CURRENT ARCHITECTURE IS UNDER STRAIN

- **Diminishing returns:** more slices, faster processing and better software layered on legacy physics
- **Structural limits:** dose vs image-quality trade-offs, fixed centralised infrastructure, high system cost
- **Rising demand:** precision, speed and flexibility needed at once – workflows are overloaded

Not a technology problem: an architecture problem – the pattern behind every prior imaging shift

NEX: A NEW ARCHITECTURE, NOT AN UPGRADE

- **Fundamentally different:** a new way of generating X-rays, not a tube variation or software enhancement
- **Solves the constraints:** lower dose, portable systems, lower cost, simpler operation, longer tube life
- **Signals aligning:** new science, major industry investment and hospital trials – how every prior shift began

Early adopters win: when signals align, value shifts to those defining the new system

CENTRALISED → DISTRIBUTED

COMPLEX → SIMPLIFIED





RESOURCE-INTENSIVE → ACCESSIBLE

**Timing is everything in disruption cycles
This is the window where new leaders are created**



CT COMMERCIAL PATHWAY

Bringing a Portfolio of Medical CT Products to Market

MICRO-X

PRODUCTS	FUNDING / STATUS	MARKET (TAM)	CY2026	CY2027	CY2028	
Mobile Head CT 	Test bench completed \$8M ASA funding to prototype delivery \$4.4M IGP Grant funding for ambulance trial	~\$9.4B near-term	Hospital and Ambulance Human Imaging Trials Product Development	Regulatory Submission Commercial Launch	Sales Growth	
Mobile Full Body CT 	Design stage Up to \$25M ARPA-H funding to prototype delivery	Extends the ~\$9.4B Head CT market	Phase 1, Design & Prototype	Phase 2 - Testing	Regulatory Submission	
Mobile X-Ray Machine 	400+ units sold to date Model update creating new opportunities and growing pipeline	Established mobile DR market	Product Update Drives Growth			Cashflow Positive Operations
Miniaturised Security Solutions 	Prototypes being tested Up to \$31.7M DHS contract to live testing	Adjacent (non-medical)	Deliver two more Checkpoints	Live testing in U.S. airport	Commercialisation Partnerships	

DEVELOPMENT



HEAD CT

Undertaking hospital imaging trials

- Complete **hospital human imaging trials** at Royal Melbourne and Royal Adelaide
- **6-9 month pivotal study** vs conventional CT in stroke patients
- Develop and trial **ambulance prototype**
- Deploy **\$4.4M IGP grant** for South Australian road ambulance trial
- Extend **air ambulance trial** via ASA with Careflight and RFDS
- Identify partnerships to **drive market access**

FULL BODY CT

Developing Full Body test bench

- Complete **\$12.5M initial ARPA-H funding** (up to \$25M over 5 years)
- Complete **first Full Body test bench**
- Design **high voltage ring and switching**
- Undertake **critical design review** with patient and clinician feedback
- Retain all IP – **builds on Head CT and Baggage CT platform**
- Progress **vehicle integration** toward FDA 510(k) submission

COMMERCIAL



MOBILE DR

Sales growth - current & new markets

- Launch **2026 model update** – lower cost, improved margins
- Roll out **Lumen HD detector**, in-bin charging and HD touchscreen
- Build on **\$3.3M Malaysian Ministry of Health order** across South-East Asia
- Convert **US Healthcare Group supply agreement** (700+ facilities)
- Grow sales via **Purchasing Groups and Healthcare Networks**
- Win **large tendering opportunities** in US, Asia and EU

PARTNERSHIPS



SECURITY

Execute security partnerships to unlock value

- Deliver **two additional DHS Checkpoint modules**
- Advance **DHS detection algorithms** for Self-Screening Passenger Checkpoint
- Complete **Billion Prima collaboration agreement**
- Launch **NEX Technology baggage scanner** with Billion Prima
- Realise value from **security technology partnerships**
- Secure **security program partner and major funding**

CORE TECHNOLOGY

X-ray Technology Shift

MICRO-X



CONVENTIONAL X-Ray

Hot filament tube

Heated wire sheds electrons, like an incandescent bulb

BULKY · INEFFICIENT



NEX by Micro-X

Cold Cathode CNT tube

Electric field releases electrons without heat, like an LED.

COMPACT · EFFICIENT

Micro-X has expanded this shift into 4 core technology components to enable multiple imaging solutions

X-RAY TUBES


HIGH VOLTAGE GENERATOR

MULTI-TUBE SWITCHING ARRAY


RECONSTRUCTION SOFTWARE




Smaller, simpler, lighter, & more efficient X-ray



Precise electronic control of X-ray tubes



Flexible and robust imaging configurations



Custom algorithms for novel CT geometries

VALIDATION & PARTNERS

Non-dilutive funding de-risks our technology development and unlocks value

DEVELOPMENT PARTNERS



Up to \$31.7M funding

Checkpoints & Baggage Scanner – U.S. Airports



Up to \$25M funding

Full Body CT – Portable & Lightweight



Australian Stroke Alliance

\$8M funding

Head CT – Stroke Diagnosis



Australian Government
Department of Industry, Science and Resources

\$4.4M funding

Head CT – Ambulance trials



>\$90M
partnership
funding

COLLABORATION PARTNERS



\$15M funding

Multibeam Emitters – Strategic investment



\$8.5M funding


Baggage & Parcel scanner – SE Asia



MICRO-X

THE CT OPPORTUNITY

Head CT & Full Body CT,
our largest addressable markets



THE STROKE PROBLEM

MICRO-X

Stroke is the leading cause of disability globally, the gap between ambulance and hospital costs lives



1 in 4 people will have a stroke in their lifetime¹




New Stroke every **3 seconds**¹



12.2M new strokes a year¹



US\$451B estimated cost of stroke in 2017¹



63% of strokes occur in people below 70¹

The diagnostic gap

- ✘ A stroke is caused by either a blocked vessel or a bleed in the brain – symptoms look similar at the scene
- ✘ **Advanced imaging** tells the difference quickly, so doctors can choose the right treatment safely
- ✘ Time-to-treatment drives outcomes: every minute of delay costs ~1.9 million neurons; the “golden hour” starts at onset, not at hospital arrival
- ✘ Advanced imaging is typically confined to hospitals – time-to-hospital and scanner availability are the key limits on early stroke treatment

TIME IS BRAIN “...FOR EVERY MINUTE SAVED IN THROMBOLYSIS, PATIENTS GAIN AN AVERAGE 1.8 DAYS OF HEALTHY LIFE. IMAGING IS CRITICAL TO UNDERSTANDING HOW FAST THE BRAIN IS DYING AND WHETHER TISSUE REMAINS SALVAGEABLE...”

Prof Tim Kleinig
Head, Royal Adelaide Hospital Comprehensive Stroke Service
Chair, State Stroke Community of Practice

1. Feigin, Valery L., et al. "World Stroke Organization (WSO): global stroke facts sheet 2022." International journal of stroke 17.1 (2022): 18-29.
2. Meretoja et al., Stroke, 2014

MOBILE STROKE UNITS: PROVEN, NOT SCALABLE

MICRO-X

Micro-X Head CT to deliver the same outcomes at a fraction of the cost

The problem

Proven: 32.9% of patients treated within 60 min vs 2.6% on standard EMS, and 25% lower mortality⁽¹⁾

Yet rare: fewer than 50 deployed globally⁽²⁾

Why: cost. ~\$1.5M to fit-out plus ~\$1M per year⁽³⁾

Dedicated vehicle and a full stroke team (RN, radiographer, EMT) that can only treat stroke

Micro-X advances pre-hospital care

10x lighter: the CT shrinks from ~700kg to ~70kg

Fits any ambulance: deploys in a standard road or air ambulance, stows for other patient call-outs

No extra staff: operable by a trained EMT, no dedicated stroke team

Fraction of the cost: ~\$230k to acquire and low cost to maintain



TODAY: full-size Mobile Stroke Unit



MICRO-X: Head CT in a standard ambulance

1. Grotta JC, et al. Prospective, multicenter, controlled trial of mobile stroke units. NEJM 385.11 (2021): 971-981. 2. Rink JS, et al. Lifetime economic potential of mobile stroke units in acute stroke care. J Telemed Telecare 30.8 (2024): 1335-1344. 3. Rink JS, et al. Mobile stroke units services in Germany. Eur J Neurol 32.1 (2025): e16514.

MOBILE STROKE UNIT: ADDRESSABLE MARKET



Our Vision: Mobile Stroke Unit for Every Ambulance

A CT in every ambulance with economics that pay for themselves

- ✦ Illustrative Deployment model: 1 EMT ambulance per 50,000 people in the US and EU; ~240 strokes a year per 100,000 people (USCDC, 2024)
- ✦ **Micro-X Head CT adds only ~US\$50k per year** per ambulance over 5 years (US\$150k purchase plus US\$20k p.a.)
- ✦ At 120 scans a year, ~US\$416 per scan vs CT reimbursement of US\$400-500 per scan
 - A conventional MSU costs ~US\$1M a year to run – ~US\$1,400 per patient across 1,200 patients

REIMBURSEMENT COVERS THE COST PER SCAN RAPID PAYBACK IN EVERY EMT AMBULANCE

	Total Ambulance	Estimated EMT Ambulances	Head CT Market Potential (AUD)
US Ambulance	70,000	7,000	\$1,610M
US Helicopter & Fixed-wing Paramedics	750	750	\$173M
AU Ambulances	5,000	500	\$115M
AU Helicopter & Fixed-wing Paramedics	100	100	\$23M
EU Ambulance	65,000	6,500	\$1,500M
EU Helicopter & Fixed-wing Paramedics	2,400	2,400	\$552M
Total		17,250	\$4.0B

1. Per-ambulance economics reflect a US example and are shown in US dollars; table market potential is shown in AUD. TAM and unit economics are based on management estimates

HEAD CT: BEYOND THE MOBILE STROKE UNIT

Bringing Head CT into Emergency Rooms, Intensive Care, & Operating Rooms

Head CT need

- ✘ **Emergency:** head trauma, stroke, severe headache, loss of consciousness, seizures
- ✘ **Intensive care:** monitoring stroke, infection, brain trauma and hydrocephalus (fluid in the brain)
- ✘ **Neurosurgery:** pre-surgical planning, intraoperative placement, post-surgical review
- ✘ ~16M head CTs a year in the US, 15M in the EU and 2.5M in AU
- ✘ Conventional full-sized CT is most often used
- ✘ A portable, lower-cost Head CT in the ER, OR or ICU increases use, reduces patient movement, and **recovers its \$230k cost at just 100-150 scans a year over its 5-year life**

	Estimated Number	Head CT Market Potential (AUD)
US Emergency Rooms/ICU	10,500	\$2,420M
US Neurosurgery Operating Rooms	1,500	\$345M
AU Emergency Rooms/ICU	720	\$166M
AU Neurosurgery Operating Rooms	31	\$7M
EU Emergency Rooms/ICU	10,000	\$2,300M
EU Neurosurgery Operating Rooms	550	\$127M
Total	23,301	\$5.4B

ROVER: TRAILBLAZING PRODUCT

Demonstrating core technology and benefits in multiple key markets

MICRO-X

FDA, TGA, CE MDR Trailblazing


- ✘ First CNT cold-cathode X-ray system globally certified by FDA, TGA and CE MDR for human imaging
 - Same core CNT and high-voltage technology as Head CT and Full Body CT
- ✘ Proving reliability and image quality across markets:
 - 400+ units sold across 38 countries
 - High-quality images at lower exposure settings
 - Used in Ukraine battle-front hospitals, US Major League Baseball, Australian in-home care and conventional hospitals

Growing Sales Opportunities Pave the Way for Head CT

- ✘ \$3.3M major tender to the Malaysian Ministry of Health
- ✘ Sales strategy reset augmented by external sales and go-to-market expertise

2026 Update

- ✘ 2026 model update available mid-year – first major refresh since 2020
- ✘ Lumen HD glass-free detector, in-bin charging & larger HD touchscreen
- ✘ Lower manufacturing cost driving improved margins
- ✘ Customer-led refresh – strengthens existing design
- ✘ Supports growth into US Healthcare networks and GPOs



Examples of different customers

SECURITY SCREENING

MICRO-X

Applying Micro-X core technology to rethink airport passenger screening



Self-Screening Passenger Checkpoint and Miniaturised CT

- ✘ NEX technology enables a new baggage CT: ¼ the size, ¼ the weight, ½ the cost of conventional airport CT
- ✘ Transforms the long conventional screening lane into a compact, automated self-screening checkpoint
- ✘ Fewer screening officers, higher throughput, better passenger experience, stronger security

DHS S&T and TSA Funded

- ✘ Funded and guided by the US DHS and TSA
- ✘ Contracted up to US\$21M (AUD\$31.7M) with US\$17.5M received to-date
- ✘ Multiple small CTs delivered to US test labs plus one complete self-screening booth

\$8.5M Billion Prima Partnership

- ✘ Billion Prima: Malaysian specialist in baggage and cargo scanning
- ✘ \$3.5M Partnership to provide small CT prototype for baggage and cargo screening
- ✘ \$5.0M invested in Micro-X – currently holds 8.6%

Seeking further Partner-led models bring security products to market and realise value



Head CT: pathway from clinical trials to commercial launch across Australia and the United States

01

Clinical Validation

- ✓ **Done** 2 x Imaging test benches delivered to ASA
- **Now** Human imaging trials; completion expected in 2026
- **Next** In Ambulance trials planned

02

Regulatory Pathway

- ✓ **Done** FDA 510(k) approval pathway identified with FDA
- **Now** Submission preparation aligned to pivotal study completion
- **Next** TGA clearance and FDA 510(k) clearance targeted; CE Mark to follow

03

Reimbursement & Access

- ✓ **Done** MBS reimbursement pathway and CPT code strategy initiated
- **Now** Pathway development in parallel with the clinical program
- **Next** Reimbursement listing post-clearance

04

Commercial Launch


- ✓ **Done** KOL and Advocacy strategy complete
- **Now** Go-to-market and distribution planning
- **Next** Launch then scaled distribution, following clearance

FULL-BODY CT NEXT-GENERATION MOBILE IMAGING MICRO-X

ARPA-H funding supports Micro-X's expansion into full-body CT imaging



Full Body CT: portable, vehicle-deployable



Compact scanner fits inside a standard vehicle

ARPA-H funding to advance full-body CT

- ✘ Initial funding of \$12.5M for first 2 years, up to **\$25M for a total of 5 years**
- ✘ Contract to design and deliver a lightweight, portable CT for rural and remote use
- ✘ Competitive award won against multiple conventional CT vendors

Complete CT imaging solution

- ✘ Targets the global gap in CT access – most acute in rural and remote regions
- ✘ Lightweight and portable CT scanner, a “hospital on wheels”
- ✘ Builds on the Head CT and Baggage CT technology platform

Staged work, all intellectual property retained

- ✘ Funding covers everything to FDA 510(k) submission, including vehicle integration and rural-US testing
- ✘ **CT prototype design in 2026**

EXPERIENCED LEADERSHIP

Execution credentials across CT, medtech, defence programs, manufacturing and commercial scale-up

MICRO-X



Kingsley Hall, CEO
25+ years' experience in senior operational and finance roles



Brian Gonzales, PhD, CEO Americas
Industry leader in X-ray physics, CNT technology and X-ray imaging



Anthony Skeats, COO
25+ years' experience in R&D, program and engineering management in high-technology products



Peter Dickman, CFO
Former Chief Performance Officer at Domino's Pizza Enterprises, with 20+ years' industry experience



Patrick O'Brien, Non-Exec Chair
Former Senior Exec. Macquarie Group, McKinsey and Minter Ellison



Jim McDowell, Non-Exec
Chair-elect ASC, NED Metal Powder Works, Former Defence Deputy Sec




Ilona Meyer, Non-Exec
General Counsel Nuix, former Boehringer Ingelheim, ResMed, Medtronic





Andrew Hartmann, Non-Exec
Senior VP Varex Imaging, former Philips, Carestream and Siemens

FINANCIAL SNAPSHOT



 **\$22.2m**
Contracted Payments FY26 onwards

 **\$13.1m**
FY25 Total Revenue

 **\$5.4m**
R&D Rebate FY25
\$5.1m received during FY25 & \$0.3m received during FY26

FINANCIALS & SHAREHOLDERS

SHARE CAPITAL (22 June 2026)

Cash	\$3.5m (31 March 2026)	Share price	\$0.037 per share
Revenue	\$13.1m (FY2025) \$10.1m (HY2026)	Total shares on issue	748.0m current
Institutions & Strategic Investors	Acom (9.5%), Perennial (8.7%), Billion Prima (8.6%), Varex (7.2%), Thomey (6.0%)	Performance rights	66.0 million
		Convertible notes	162.5k shares
Board & Mgmt	2.5% excl. Performance rights	Market cap	\$27.7 million

MICRO-X

For more information visit: www.micro-x.com

Micro-X Limited

Kingsley Hall, Chief Executive Officer
Rebecca Puddy, Head of Corporate
Communications
Tel: +61 8 7099 3966
Email: media@micro-x.com

Investor Enquiries

Peter Dickman, Chief Financial Officer
Tel: +61 8 7099 3966
Email: pdickman@micro-x.com



ARPA-H Advanced Research Projects Agency for Health (USA)

ASA Australian Stroke Alliance

CDC Center for Disease Control and Prevention (USA)

CE (MDR) European conformity mark (Medical Device Regulation)

CNT Carbon nanotube (Micro-X X-ray emitter technology)

CPT Current Procedural Terminology (US billing codes)

CT Computed tomography

DHS Department of Homeland Security (USA)

DR Digital radiography (mobile X-ray)

EMS Emergency medical services

EMT Emergency medical technician / ambulance

ER Emergency room

FDA 510(k) Food and Drug Administration clearance pathway (USA)

GPO Group purchasing organisation

ICU Intensive care unit

IGP Industry Growth Program (Australian Government)

MBS Medicare Benefits Schedule (Australia)

MRFF Medical Research Future Fund (Australia)

MSU Mobile stroke unit

NEX Nano Electronic X-ray (Micro-X core platform)

RFDS Royal Flying Doctor Service (Australia)

tPA Tissue plasminogen activator (stroke clot-buster drug)

TAM Total addressable market

TGA Therapeutic Goods Administration (Australia)

TSA Transportation Security Administration (USA)